aviscera bioscience  
Order : (408) 982 0300
line decor
  HOME  ::  
line decor
Soluble CD21(Human) ELISA, Protein & Antibody
A dendritic cell marker 

Alternative name:

  • Complement receptor type 2
  • Complement C3d receptor
  • Epstein-Barr virus receptor
  • CD_antigen=CD21

Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma


METHODS:The clinical data from 80 DLBCL patients who were treated in First Hospital of Jilin University from June 2005 to September 2011 were retrospectively analyzed. The cases were subjected to immunohistochemical staining (SP method) for Ki-67, CD20, CD79a, CD3, CD43, CD5, cyclin D1, bcl-2, CD10, bcl-6, GCET-1, FOXP-1 and MUM-1 protein expression in the tumor tissue. Immunohistochemistry was also used to detect CD21expression in the tumor tissue. SPSS 18.0 was used to analyze the relationship between CD21 expression and various clinical factors, and the relationship between various clinical factors including CD21 and overall survival. RESULTS:In the patients aged under 60 years, the incidence of CD21(+) lymphoma (64.0%, 16/25) was significantly higher than that of CD21(-) lymphoma (38.2%, 21/55). There were more CD21(+) lymphoma patients who were at clinical stages I-II (52.0%, 13/25) than patients with CD21(-)lymphomas (23.6%, 13/55). There were also more CD21(+) lymphoma patients (68.0%, 17/25) having less than two extranodal sites involvement thanCD21(-)lymphoma patients (41.8%, 23/55). In addition, there were more CD21(+) lymphoma patients with IPI 0-2 (68.0%, 17/25) than CD21(-)lymphoma patients (41.8%, 23/55). There were more CD21(+) lymphoma patients with GCB subtype (60.0%, 15/25) than CD21(-)lymphoma patients (23.6%, 13/55). Death related to DLBCL was less in CD21(+) lymphoma patients (32.0%, 8/25) than CD21(-) lymphoma patients (56.4%, 31/55). Univariate analysis showed that these clinical pathological characteristics affected the overall survival of DLBCL patients, including age, ECOG score, LDH, extranodal involvement, IPI index, CD21 expression, treatment option and efficacy (P < 0.05) . Cox multivariate analysis showed that ECOG score, LDH, extranodal involvement, CD21 expression were closely related to prognosis, and the difference was statistically significant (P < 0.05). Among the 80 patients, the overall survival (OS) of CD21(+) lymphoma patients was significantly higher than that of CD21(-) lymphoma patients. CONCLUSIONS:The expression of CD21 is associated with young age at onset, early clinical stage, small number of involvement and low IPI index. The OS and median overall survival of CD21(+) lymphoma patients are significantly higher than those of CD21(-) patients. CD21 expression, ECOG score, LDH, extranodal involvement are independent prognostic factors in DLBCL, and in particular, the expression of CD21 is more significant in the prognosis of DLBCL patients.

Yao WK,  et al. Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):818-22. 

Serum levels of soluble CD21 in patients with systemic sclerosis

Systemic sclerosis (SSc) is a systemic disorder that typically results in fibrosis of the skin and multiple internal organ systems. Although the precise mechanism is unknown, overproduction of extracellular matrix proteins, including collagens and fibronectins, and aberrant immune activation might be involved in the pathogenesis. The soluble cluster of differentiation 21 (sCD21) represents the extracellular portion of the CD21 glycoprotein that is released by shedding from the cell surfaces into plasma. sCD21 binds complement fragments and activates monocytes through binding to membrane CD23. The present study was undertaken to investigate the serum levels of sCD21 in patients with SSc. Serum sCD21 levels were reduced with age both in patients with SSc and normal controls. Serum sCD21 levels in patients with SSc were significantly decreased compared to those in control subjects. When we divided patients with SSc into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), patients with lcSSc had lower levels of serum sCD21 than those with dcSSc. Moreover, the prevalence of pulmonary fibrosis in the patients with dcSSc inversely correlated with serum sCD21 levels. Our finding may support the notion that B-cell activation is involved in the mechanism for pulmonary fibrosis and skin sclerosis.
Tomita M, et al.Rheumatol Int. 2012 Feb;32(2):317-21  
human soluble CD21 elisa kit enables to measure human samples from aviscera bioscience
human soluble cd21 elisa kit
Human Soluble CD21 ELISA Kit
Code No.: SK00620-01
Size: 96 T
Price: $420.00
Standard range:31-2000 pg/ml
Sensitivity: 15 pg/ml
Sample Type:serum, plasma
Dilution Factor:200-400 for serum or plasma
Sample require: 100 ul of diluted samples per well
Intra-CV: 6-8%
Inter-CV: 8-12%
Data Sheet: PDF



Code No.
Price ($)
Human Soluble CD21 ELISA Kit SK00620-01 96 T 420.00
Soluble CD21 (human) Standard for ELISA 620-01-02 each 80.00
Soluble CD21 (human) Rec (HEK293) 00620-07-1000 1 mg inquire
Anti soluble CD21 (human) IgG for western blot, IHC A00620-05-50 50 ug 260.00